ORAMED PHARMACEUTICALS WKN: A1CTNU ISIN: US68403P2039 Kürzel: ORMP Forum: Aktien Thema: Hauptdiskussion

Der Bekanntheitsgrad von Oramed hat die Tage beachtlich zugelegt. Kann Dr Aktie nicht schaden wenn sie zurecht mehr Aufmerksamkeit bekommt. Aus Zack Investment Research: Advantages include ease of storage & distribution, plus potential to overcome vaccine hesitancy Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has announced the formation of a new joint venture with India-based Premas Biotech, Oravax Medical Inc., to advance an orally administered vaccine for the COVID-19 virus. Oramed is the largest shareholder of Oravax, which will leverage Oramed’s proprietary POD™ oral delivery technology and Premas Biotech’s novel vaccine technology. Oravax intends to launch and commercialize its oral COVID-19 vaccine following clinical trials. In a preclinical study of its efficacy, the oral vaccine successfully produced antibodies after just one dose. It promoted systemic immunity through Immunoglobulin G (IgG), which is the most common antibody in the blood and bodily fluids protecting against viral infections, and through Immunoglobulin A (IgA), which are antibodies that are found in the lungs, sinuses, stomach, and intestines that protect the respiratory and gastrointestinal tracts against infection. In addition to offering protection against current COVID-19 strains, Oramed also believes that the oral vaccine could protect against emerging coronavirus variants more than many other vaccines currently being administered because of its triple antigen targeting of three structural protein parts of the SARS CoV-2 virus: Spike (S), Membrane M, and coronavirus envelope E targets. Based on Premas’ novel technology, the Oravax pill is a virus-like particle (VLP) triple antigen vaccine. VLPs are molecules that are similar to viruses but are not infectious. According to News Medical, using VLPs is “a very effective way of creating vaccines.” Moreover, given the difficulties involved in storing and distributing most COVID-19 vaccines currently being offered, the Oravax vaccine might also provide a more convenient way to provide wide-scale distribution and inoculation as, unlike most other vaccines that require freezing storage, the Oravax vaccine can be stored in standard refrigerators. A pill format would also enable people to fill a prescription and then take the pill vaccine in the comfort of their own homes, eliminating the inconvenience of seeking vaccine availability and then waiting at an external location to receive the dose. In turn, this might enable health agencies to boost inoculation rates. Currently, about 14% of people nationwide in the U.S. and less than 1% globally have been fully vaccinated, according to the New York Times, with a “striking divide” from one country to another. With higher portions of the population inoculated against COVID-19, we would expect commercial activity to resume towards pre-pandemic levels. The company believes that a pill is probably also a greener vaccine option than a single- or double-dose injection solution that produces needles that have to be discarded. Depending on packaging of the Oravax oral vaccine, this could be an important differentiating factor from an environmental, social and corporate governance (ESG) investing perspective. We believe ESG is an increasingly important component of overall investment decision making. .

https://tdameritradenetwork.com/video/rB4A-HhkFsiBeGWlqzYAkw

Hi nionus. Hast du die Quellenangabe? Danke im Voraus.

Ohne Berücksichtigung der Covid-Studie

Medial Research: Kursziel: 23 Dollar

Ora et Labora : Sie arbeiten dort, wir können nur beten. :)

Nur

Nicht. Je bei dir

Alles was ich kaufe wird zu roten Zahlen, love it

Ciao

https://finance.yahoo.com/news/oramed-initiates-second-phase-3-125100657.html

https://www.msn.com/de-de/lifestyle/other/corona-hammer-forscher-entwickeln-neue-impfung-zum-schlucken/ar-BB1eUfVs?ocid=uxbndlbing

Hatte gestern nicht gedacht, dass es so schnell wieder unter 10 geht sogar. Jetzt denke ich wir könnten sogar ca. 8,40 heute noch sehen. Wenn alles so läuft, wie bei der Nadel Anfang-Dezember dauert es nun 2 Monate bis wir dann reell bei 16 sind, vielleicht, wenn dann erste Ergebnisse aus der Insulin-Phase-III-Studie veröffentlicht werden. Und bis dahin könnt man sich auch zu Kursen um die 7,50 einmal sogar wieder rein.

@FCINGO, ja, nur gestern kannte ich hier dieses Forum noch nicht. :( Hat Börsennews eigentlich automatisch zu jeder Aktie ein Forum??? War überrascht für so einen bislang relativ unbekannten Wert ...

@Hubbra , ja vorgestern, sehr, sehr ärgerlich. War ja also genau noch richtig dabei, eigentlich und hatte auch alles rechtzeitig gesehen ... aber eigentlich anderweitig beschäftigt ...

Moin Moin. Ich hatte doch gestern geschrieben das der Anstieg völlig übertrieben ist. Hoffe ihr habt eure Gewinne rausgeholt oder Saschkia ?